NCT02144285View on ClinicalTrials.gov

A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Kidney Failure, Chronic
Interventions
DRUG

LY3113593

Administered IV

DRUG

LY3113593

Administered SC

DRUG

Placebo

Administered IV

DRUG

Placebo

Administered SC

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

55404

Davita Clinical Research, Minneapolis

91206

Parexel Early Phase Unit at Glendale, Glendale

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02144285 - A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis | Biotech Hunter | Biotech Hunter